Skip to content

Study · Randomized controlled trial · n = 6 · 1988

2 results

Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction.

Crimi N, Palermo F, Oliveri R, Palermo B, Vancheri C, Polosa R, Mistretta A

The Journal of allergy and clinical immunology1 Oct 1988Cited by 10 (Europe PMC)

PMID2971708 (opens in a new tab)DOI10.1016/0091-6749(88)90973-6 (opens in a new tab)PepBankPUB-02971708
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In six patients with asthma, inhaled VIP significantly raised the propranolol dose needed to cause a 20% fall in FEV1 (PD20).

    In plain wordsIn patients with asthma, inhaled VIP made a larger dose of propranolol necessary to narrow the airways.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePropranolol PD20 after VIP
    Study

    n = 6

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    70 micrograms · inhalationAs given in this study (human).

    Source sentences

    Summary
    Ipratropium bromide administration, like VIP administration, significantly raised the PD20 value.
    2 context sentences
    Summary · context
    The study was performed in six patients with asthma in 4 days.
    Summary · context
    On the other days, the propranolol challenge was performed after inhalation of ipratropium bromide (40 micrograms), VIP (70 micrograms), and both drugs in randomized double-blind order.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialEfficacy outcome

    In six patients with asthma, inhaled VIP together with ipratropium bromide gave a further increase in mean propranolol PD20.

    In plain wordsIn patients with asthma, inhaled VIP together with ipratropium bromide raised the propranolol dose needed to narrow the airways even further.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePropranolol PD20 after VIP plus ipratropium
    Study

    n = 6

    Outcome group
    Respiratory function · Respiratory

    Source sentences

    Summary
    The administration of both drugs elicited a further remarkable increase of mean propranolol PD20.
    2 context sentences
    Summary · context
    The study was performed in six patients with asthma in 4 days.
    Summary · context
    On the other days, the propranolol challenge was performed after inhalation of ipratropium bromide (40 micrograms), VIP (70 micrograms), and both drugs in randomized double-blind order.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.